A whole-exome sequencing (WES) of baseline tumor biopsies from 64 melanoma patients receiving CTLA-4 inhibitors (ipilimumab or tremelimumab) revealed over 100 somatic mutations related to a degree of clinical benefit within 6 months of therapy in responding patients (p = 0.01). This evidence concerns the gene CTLA4 and melanoma.